Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2469
Abstract: This prespecified analysis of the FIDELIO‐DKD trial compared the effects of finerenone, a selective non‐steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) by history… read more here.
Keywords: heart failure; dkd trial; analysis fidelio; fidelio dkd ... See more keywords